Blog

Pharmalittle: Biogen argues investors overreacted; AstraZeneca wins a key immunotherapy approval – STAT


STAT

Pharmalittle: Biogen argues investors overreacted; AstraZeneca wins a key immunotherapy approval
STAT
ood morning, everyone, and welcome to another working week. Those of you on our side of the pond had, of course, an extended respite thanks to a federal holiday, and we hope your time was relaxing and invigorating, because that oh-so-familiar routine
US FDA Approves AstraZeneca's Immunotherapy for Lung CancerJournal of Clinical Pathways


AstraZeneca PLC (NYSE:AZN) won crucial approval from US regulators for use in lung cancerBenchmark Monitor

all 5 news articles »

2018-02-20 NEWS
About Michael Zand

Leave a Reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.